Brian Rini, MD Profile
Brian Rini, MD

@brian_rini

Followers
6K
Following
2K
Media
172
Statuses
2K

Nashville, TN
Joined June 2014
Don't wanna be here? Send us removal request.
@brian_rini
Brian Rini, MD
7 hours
RT @TresUramigas: #KCRS25 En RCC, VEGF/HIF y PD1/CTLA4 han mejorado resultados en 1-2L. Faltan datos en combos con nuevos HIF (casdatifan),….
0
5
0
@brian_rini
Brian Rini, MD
7 hours
RT @TresUramigas: #KCRS25 @AlbigesL .KNB67 (nccRCC) : Pembro+lenva muestra eficacia sostenida a 3 años en 1L. 📌ORR 51% (10% RC).📌DOR 23.5m….
0
5
0
@brian_rini
Brian Rini, MD
7 hours
RT @Uromigos: 🚨Introducing the IMPACT series. In these episodes, The Uromigos conduct deep dives with their peers on papers that influenced….
0
5
0
@brian_rini
Brian Rini, MD
20 hours
RT @JAMAOnc: Among cancer patients, #COVID19 poses heightened risks particularly for those with hematologic malignancies and underlying hea….
0
3
0
@brian_rini
Brian Rini, MD
20 hours
RT @tmprowell: #MedTwitter .Prospective obs study: people w/ #cancer (active therapy or past HSCT or CAR-T) + pos #SARSCoV2 test in last 14….
0
1
0
@brian_rini
Brian Rini, MD
20 hours
RT @Uromigos: Hidden gem 💎 💎 #KCRS25 The CONTACT3 trial showed sequencing PD1 and PDL1 therapy was not benificisl in renal cancer. @BradMcG….
0
15
0
@brian_rini
Brian Rini, MD
5 days
RT @TresUramigas: 🏃El ejercicio estructurado postQT en ca colon estadio II/III demuestra beneficio en SLE (HR 0.72):.📌SLE 5 años: 74% vs 80….
0
6
0
@brian_rini
Brian Rini, MD
5 days
RT @Uromigos: Listen to the first installment of our IMPACT series. Axel Bex joins us to discuss impactful clinical trials in RCC. We discu….
0
5
0
@brian_rini
Brian Rini, MD
8 days
RT @TresUramigas: 🚨 Aprobado en 🇪🇺: durvalumab (Imfinzi) como IO perioperatoria para #MIBC. Ensayo NIAGARA fase III:.📌 -32% riesgo recaída….
0
5
0
@brian_rini
Brian Rini, MD
8 days
RT @montypal: Just listened to this - terrific podcast with Christopher Booth. Definitely gets you thinking of how we might test this inter….
0
2
0
@brian_rini
Brian Rini, MD
8 days
RT @TresUramigas: 🔗 @Annals_Oncology . ¿Qué se necesita para lograr ensayos neoadyuvantes que cambien la práctica en ca renal?. Estudio Del….
0
5
0
@brian_rini
Brian Rini, MD
8 days
RT @Uromigos: Professor Christopher Booth of Queen’s University in Kingston, Ontario, Canada, joins the show to discuss his recent NEJM pap….
0
9
0
@brian_rini
Brian Rini, MD
11 days
RT @Uromigos: The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour wit….
0
16
0
@brian_rini
Brian Rini, MD
18 days
RT @Uromigos: In this special episode Joshua Meeks, MD, PhD, of Northwestern Medicine, joins the Uromigos to give a stellar overview of eme….
0
7
0
@brian_rini
Brian Rini, MD
21 days
RT @tompowles1: With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to….
0
75
0
@brian_rini
Brian Rini, MD
22 days
RT @TresUramigas: A propósito del #GUARDSymposium2025. 🔍Repasamos los F3 en 1LmRCC. 📌 Todos los combos con IO mejoran OS, PFS, ORR vs TKI s….
0
13
0
@brian_rini
Brian Rini, MD
22 days
RT @TresUramigas: En 🇺🇸 se avanza rápidamente en NMIBC post-BCG: FDA ha aprobado combinaciones en estudios sin brazo control. 🤔 Los fármaco….
0
5
0
@brian_rini
Brian Rini, MD
22 days
RT @TresUramigas: 🎙️ @tompowles1 y @brian_rini os invitan al IV Encuentro Anual #UromigosLive.📍 Nashville | 🗓️ 7–8 nov.🌎 Encuentro internac….
0
5
0
@brian_rini
Brian Rini, MD
22 days
RT @TresUramigas: #GUARDSymposium2025.@JaviMolinaC .Protagonismo para KIM-1 como bmk pronóstico y posible valor predictivo en IO.📊 Necesit….
0
8
0